<DOC>
	<DOC>NCT00761306</DOC>
	<brief_summary>The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.</brief_summary>
	<brief_title>Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients who completed 6week shortterm treatment study for Major Depressive Episode (MDE), NCT00839423 / 11492A, followed by a 2week taper period Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSMIV TR) Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Long-term</keyword>
	<keyword>Safety</keyword>
	<keyword>Open-label</keyword>
</DOC>